Copyright © 2009 Emmanuel A. Tsochatzis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. G. Marchesini, E. Bugianesi, G. Forlani, et al., “Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome,” Hepatology, vol. 37, no. 4, pp. 917–923, 2003. View at Publisher · View at Google Scholar · View at PubMed
2. E. Tsochatzis, G. V. Papatheodoridis, E. K. Manesis, G. Kafiri, D. G. Tiniakos, and A. J. Archimandritis, “Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis,” Alimentary Pharmacology and Therapeutics, vol. 27, no. 1, pp. 80–89, 2008. View at Publisher · View at Google Scholar · View at PubMed
3. E. A. Tsochatzis, S. Manolakopoulos, G. V. Papatheodoridis, and A. J. Archimandritis, “Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications,” Scandinavian Journal of Gastroenterology, vol. 44, no. 1, pp. 6–14, 2009. View at Publisher · View at Google Scholar · View at PubMed
4. S. Bellentani, G. Saccoccio, F. Masutti, et al., “Prevalence of and risk factors for hepatic steatosis in Northern Italy,” Annals of Internal Medicine, vol. 132, no. 2, pp. 112–117, 2000.
5. J. D. Browning, L. S. Szczepaniak, R. Dobbins, et al., “Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity,” Hepatology, vol. 40, no. 6, pp. 1387–1395, 2004. View at Publisher · View at Google Scholar · View at PubMed
6. G. V. Papatheodoridis, J. Goulis, D. Christodoulou, et al., “High prevalence of elevated liver enzymes in blood donors: associations with male gender and central adiposity,” European Journal of Gastroenterology & Hepatology, vol. 19, no. 4, pp. 281–287, 2007. View at Publisher · View at Google Scholar · View at PubMed
7. G. C. Farrell and C. Z. Larter, “Nonalcoholic fatty liver disease: from steatosis to cirrhosis,” Hepatology, vol. 43, no. 2, supplement 1, pp. S99–S112, 2006. View at Publisher · View at Google Scholar · View at PubMed
8. C. P. Day and O. F. W. James, “Steatohepatitis: a tale of two “hits”?,” Gastroenterology, vol. 114, no. 4, pp. 842–845, 1998. View at Publisher · View at Google Scholar
9. L. A. Adams, J. F. Lymp, J. St. Sauver, et al., “The natural history of nonalcoholic fatty liver disease: a population-based cohort study,” Gastroenterology, vol. 129, no. 1, pp. 113–121, 2005. View at Publisher · View at Google Scholar
10. M. Ekstedt, L. E. Franzén, U. L. Mathiesen, et al., “Long-term follow-up of patients with NAFLD and elevated liver enzymes,” Hepatology, vol. 44, no. 4, pp. 865–873, 2006. View at Publisher · View at Google Scholar · View at PubMed
11. A. Wieckowska, A. J. McCullough, and A. E. Feldstein, “Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future,” Hepatology, vol. 46, no. 2, pp. 582–589, 2007. View at Publisher · View at Google Scholar · View at PubMed
12. E. Tsochatzis, G. V. Papatheodoridis, and A. J. Archimandritis, “The evolving role of leptin and adiponectin in chronic liver diseases,” The American Journal of Gastroenterology, vol. 101, no. 11, pp. 2629–2640, 2006. View at Publisher · View at Google Scholar · View at PubMed
13. A. S. Greenberg and M. S. Obin, “Obesity and the role of adipose tissue in inflammation and metabolism,” American Journal of Clinical Nutrition, vol. 83, no. 2, pp. 461S–465S, 2006.
14. Y. Kamada, T. Takehara, and N. Hayashi, “Adipocytokines and liver disease,” Journal of Gastroenterology, vol. 43, no. 11, pp. 811–822, 2008. View at Publisher · View at Google Scholar · View at PubMed
15. R. N. Bergman, “New concepts in extracellular signaling for insulin action: the single gateway hypothesis,” Recent Progress in Hormone Research, vol. 52, pp. 359–385, 1997.
16. E. Bugianesi, A. J. McCullough, and G. Marchesini, “Insulin resistance: a metabolic pathway to chronic liver disease,” Hepatology, vol. 42, no. 5, pp. 987–1000, 2005. View at Publisher · View at Google Scholar · View at PubMed
17. P. Angulo, “Nonalcoholic fatty liver disease,” The New England Journal of Medicine, vol. 346, no. 16, pp. 1221–1231, 2002. View at Publisher · View at Google Scholar · View at PubMed
18. D. Pessayre and B. Fromenty, “NASH: a mitochondrial disease,” Journal of Hepatology, vol. 42, no. 6, pp. 928–940, 2005. View at Publisher · View at Google Scholar · View at PubMed
19. M. Curzio, H. Esterbauer, G. Poli, et al., “Possible role of aldehydic lipid peroxidation products as chemoattractants,” International Journal of Tissue Reactions, vol. 9, no. 4, pp. 295–306, 1987.
20. H. Hug, S. Strand, A. Grambihler, et al., “Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells,” The Journal of Biological Chemistry, vol. 272, no. 45, pp. 28191–28193, 1997. View at Publisher · View at Google Scholar
21. G. Leonarduzzi, A. Scavazza, F. Biasi, et al., “The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor beta1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis,” The FASEB Journal, vol. 11, no. 11, pp. 851–857, 1997.
22. I. R. Wanless and K. Shiota, “The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis,” Seminars in Liver Disease, vol. 24, no. 1, pp. 99–106, 2004. View at Publisher · View at Google Scholar · View at PubMed
23. Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, and J. M. Friedman, “Positional cloning of the mouse obese gene and its human homologue,” Nature, vol. 372, no. 6505, pp. 425–432, 1994. View at Publisher · View at Google Scholar · View at PubMed
24. C. S. Mantzoros, “The role of leptin in human obesity and disease: a review of current evidence,” Annals of Internal Medicine, vol. 130, no. 8, pp. 671–680, 1999.
25. R. H. Unger, “Lipotoxic diseases,” Annual Review of Medicine, vol. 53, pp. 319–336, 2002. View at Publisher · View at Google Scholar · View at PubMed
26. T. Kakuma, Y. Lee, M. Higa, et al., “Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 15, pp. 8536–8541, 2000. View at Publisher · View at Google Scholar
27. K. Ikejima, H. Honda, M. Yoshikawa, et al., “Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals,” Hepatology, vol. 34, no. 2, pp. 288–297, 2001. View at Publisher · View at Google Scholar · View at PubMed
28. F. Marra, “Leptin and liver fibrosis: a matter of fat,” Gastroenterology, vol. 122, no. 5, pp. 1529–1532, 2002. View at Publisher · View at Google Scholar
29. K. Ikejima, Y. Takei, H. Honda, et al., “Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat,” Gastroenterology, vol. 122, no. 5, pp. 1399–1410, 2002. View at Publisher · View at Google Scholar
30. N. K. Saxena, K. Ikeda, D. C. Rockey, S. L. Friedman, and F. A. Anania, “Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice,” Hepatology, vol. 35, no. 4, pp. 762–771, 2002. View at Publisher · View at Google Scholar · View at PubMed
31. U. B. Pajvani, X. Du, T. P. Combs, et al., “Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity,” The Journal of Biological Chemistry, vol. 278, no. 11, pp. 9073–9085, 2003. View at Publisher · View at Google Scholar · View at PubMed
32. J. Bełtowski, “Adiponectin and resistin—new hormones of white adipose tissue,” Medical Science Monitor, vol. 9, no. 2, pp. RA55–RA61, 2003.
33. F. A. Anania, “Adiponectin and alcoholic fatty liver: is it, after all, about what you eat?,” Hepatology, vol. 42, no. 3, pp. 530–532, 2005. View at Publisher · View at Google Scholar · View at PubMed
34. M. You, R. V. Considine, T. C. Leone, D. P. Kelly, and D. W. Crabb, “Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice,” Hepatology, vol. 42, no. 3, pp. 568–577, 2005. View at Publisher · View at Google Scholar · View at PubMed
35. S. Shklyaev, G. Aslanidi, M. Tennant, et al., “Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 24, pp. 14217–14222, 2003. View at Publisher · View at Google Scholar · View at PubMed
36. Y. Kamada, H. Matsumoto, S. Tamura, et al., “Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model,” Journal of Hepatology, vol. 47, no. 4, pp. 556–564, 2007. View at Publisher · View at Google Scholar · View at PubMed
37. T. Masaki, S. Chiba, H. Tatsukawa, et al., “Adiponectin protects LPS-induced liver injury through modulation of TNF-$\alpha$ in KK-Ay obese mice,” Hepatology, vol. 40, no. 1, pp. 177–184, 2004. View at Publisher · View at Google Scholar · View at PubMed
38. A. Xu, Y. Wang, H. Keshaw, L. Y. Xu, K. S. L. Lam, and G. J. S. Cooper, “The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice,” The Journal of Clinical Investigation, vol. 112, no. 1, pp. 91–100, 2003. View at Publisher · View at Google Scholar · View at PubMed
39. K. Tomita, Y. Oike, T. Teratani, et al., “Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice,” Hepatology, vol. 48, no. 2, pp. 458–473, 2008. View at Publisher · View at Google Scholar · View at PubMed
40. G. S. Hotamisligil, N. S. Shargill, and B. M. Spiegelman, “Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance,” Science, vol. 259, no. 5091, pp. 87–91, 1993. View at Publisher · View at Google Scholar
41. K. E. Wellen and G. S. Hotamisligil, “Obesity-induced inflammatory changes in adipose tissue,” The Journal of Clinical Investigation, vol. 112, no. 12, pp. 1785–1788, 2003. View at Publisher · View at Google Scholar
42. L. Valenti, A. L. Fracanzani, P. Dongiovanni, et al., “Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease,” Gastroenterology, vol. 122, no. 2, pp. 274–280, 2002. View at Publisher · View at Google Scholar
43. K. Tokushige, M. Takakura, N. Tsuchiya-Matsushita, M. Taniai, E. Hashimoto, and K. Shiratori, “Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis,” Journal of Hepatology, vol. 46, no. 6, pp. 1104–1110, 2007. View at Publisher · View at Google Scholar · View at PubMed
44. J. Poniachik, A. Csendes, J. C. Díaz, et al., “Increased production of IL-1$\alpha$ and TNF-$\alpha$ in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease,” Cytokine, vol. 33, no. 5, pp. 252–257, 2006. View at Publisher · View at Google Scholar · View at PubMed
45. A. E. Feldstein, N. W. Werneburg, A. Canbay, et al., “Free fatty acids promote hepatic lipotoxicity by stimulating TNF-$\alpha$ expression via a lysosomal pathway,” Hepatology, vol. 40, no. 1, pp. 185–194, 2004. View at Publisher · View at Google Scholar · View at PubMed
46. K. Tomita, G. Tamiya, S. Ando, et al., “Tumour necrosis factor α signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice,” Gut, vol. 55, no. 3, pp. 415–424, 2006. View at Publisher · View at Google Scholar · View at PubMed
47. Z. Li, S. Yang, H. Lin, et al., “Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease,” Hepatology, vol. 37, no. 2, pp. 343–350, 2003. View at Publisher · View at Google Scholar · View at PubMed
48. L. Patel, A. C. Buckels, I. J. Kinghorn, et al., “Resistin is expressed in human macrophages and directly regulated by PPAR$\gamma$ activators,” Biochemical and Biophysical Research Communications, vol. 300, no. 2, pp. 472–476, 2003. View at Publisher · View at Google Scholar
49. M. Pravenec, L. Kazdová, V. Landa, et al., “Transgenic and recombinant resistin impair skeletal muscle glucose metabolism in the spontaneously hypertensive rat,” The Journal of Biological Chemistry, vol. 278, no. 46, pp. 45209–45215, 2003. View at Publisher · View at Google Scholar · View at PubMed
50. M. W. Rajala, S. Obici, P. E. Scherer, and L. Rossetti, “Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production,” The Journal of Clinical Investigation, vol. 111, no. 2, pp. 225–230, 2003.
51. S. M. Rangwala, A. S. Rich, B. Rhoades, et al., “Abnormal glucose homeostasis due to chronic hyperresistinemia,” Diabetes, vol. 53, no. 8, pp. 1937–1941, 2004. View at Publisher · View at Google Scholar
52. H. Satoh, M. T. A. Nguyen, P. D. G. Miles, T. Imamura, I. Usui, and J. M. Olefsky, “Adenovirus-mediated chronic “hyper-resistinemia” leads to in vivo insulin resistance in normal rats,” The Journal of Clinical Investigation, vol. 114, no. 2, pp. 224–231, 2004. View at Publisher · View at Google Scholar
53. R. Palanivel and G. Sweeney, “Regulation of fatty acid uptake and metabolism in L6 skeletal muscle cells by resistin,” FEBS Letters, vol. 579, no. 22, pp. 5049–5054, 2005. View at Publisher · View at Google Scholar · View at PubMed
54. C. M. Steppan, J. Wang, E. L. Whiteman, M. J. Birnbaum, and M. A. Lazar, “Activation of SOCS-3 by resistin,” Molecular and Cellular Biology, vol. 25, no. 4, pp. 1569–1575, 2005. View at Publisher · View at Google Scholar · View at PubMed
55. N. Silswal, A. K. Singh, B. Aruna, S. Mukhopadhyay, S. Ghosh, and N. Z. Ehtesham, “Human resistin stimulates the pro-inflammatory cytokines TNF-$\alpha$ and IL-12 in macrophages by NF-$\kappa$B-dependent pathway,” Biochemical and Biophysical Research Communications, vol. 334, no. 4, pp. 1092–1101, 2005. View at Publisher · View at Google Scholar · View at PubMed
56. M. Bokarewa, I. Nagaev, L. Dahlberg, U. Smith, and A. Tarkowski, “Resistin, an adipokine with potent proinflammatory properties,” The Journal of Immunology, vol. 174, no. 9, pp. 5789–5795, 2005.
57. C. Bertolani, P. Sancho-Bru, P. Failli, et al., “Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells,” American Journal of Pathology, vol. 169, no. 6, pp. 2042–2053, 2006. View at Publisher · View at Google Scholar
58. D. E. Cressman, L. E. Greenbaum, R. A. DeAngelis, et al., “Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice,” Science, vol. 274, no. 5291, pp. 1379–1383, 1996. View at Publisher · View at Google Scholar
59. O. El-Assal, F. Hong, W. H. Kim, S. Radaeva, and B. Gao, “IL-6-deficient mice are susceptible to ethanol-induced hepatic steatosis: IL-6 protects against ethanol-induced oxidative stress and mitochondrial permeability transition in the liver,” Cellular & Molecular Immunology, vol. 1, no. 3, pp. 205–211, 2004.
60. N. Teoh, J. Field, and G. Farrell, “Interleukin-6 is a key mediator of the hepatoprotective and pro-proliferative effects of ischaemic preconditioning in mice,” Journal of Hepatology, vol. 45, no. 1, pp. 20–27, 2006. View at Publisher · View at Google Scholar · View at PubMed
61. A. Blindenbacher, X. Wang, I. Langer, R. Savino, L. Terracciano, and M. H. Heim, “Interleukin 6 is important for survival after partial hepatectomy in mice,” Hepatology, vol. 38, no. 3, pp. 674–682, 2003. View at Publisher · View at Google Scholar · View at PubMed
62. X. Jin, T. A. Zimmers, E. A. Perez, R. H. Pierce, Z. Zhang, and L. G. Koniaris, “Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair,” Hepatology, vol. 43, no. 3, pp. 474–484, 2006. View at Publisher · View at Google Scholar · View at PubMed
63. Q. Yang, T. E. Graham, N. Mody, et al., “Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes,” Nature, vol. 436, no. 7049, pp. 356–362, 2005. View at Publisher · View at Google Scholar · View at PubMed
64. T. E. Graham, Q. Yang, M. Blüher, et al., “Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects,” The New England Journal of Medicine, vol. 354, no. 24, pp. 2552–2563, 2006. View at Publisher · View at Google Scholar · View at PubMed
65. N. Klöting, T. E. Graham, J. Berndt, et al., “Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass,” Cell Metabolism, vol. 6, no. 1, pp. 79–87, 2007. View at Publisher · View at Google Scholar · View at PubMed
66. P. Balagopal, T. E. Graham, B. B. Kahn, A. Altomare, V. Funanage, and D. George, “Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 5, pp. 1971–1974, 2007. View at Publisher · View at Google Scholar · View at PubMed
67. A. Yao-Borengasser, V. Varma, A. M. Bodles, et al., “Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 7, pp. 2590–2597, 2007. View at Publisher · View at Google Scholar · View at PubMed
68. A. Fukuhara, M. Matsuda, M. Nishizawa, et al., “Visfatin: a protein secreted by visceral fat that Mimics the effects of insulin,” Science, vol. 307, no. 5708, pp. 426–430, 2005. View at Publisher · View at Google Scholar · View at PubMed
69. S. Chitturi, G. Farrell, L. Frost, et al., “Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?,” Hepatology, vol. 36, no. 2, pp. 403–409, 2002. View at Publisher · View at Google Scholar · View at PubMed
70. P. Angulo, L. M. Alba, L. M. Petrovic, L. A. Adams, K. D. Lindor, and M. D. Jensen, “Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease,” Journal of Hepatology, vol. 41, no. 6, pp. 943–949, 2004. View at Publisher · View at Google Scholar · View at PubMed
71. N. Chalasani, D. W. Crabb, O. W. Cummings, et al., “Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis?,” The American Journal of Gastroenterology, vol. 98, no. 12, pp. 2771–2776, 2003. View at Publisher · View at Google Scholar · View at PubMed
72. G. Musso, R. Gambino, M. Durazzo, et al., “Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease,” Hepatology, vol. 42, no. 5, pp. 1175–1183, 2005. View at Publisher · View at Google Scholar · View at PubMed
73. E. Tsochatzis, G. V. Papatheodoridis, E. Hadziyannis, et al., “Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity,” Scandinavian Journal of Gastroenterology, vol. 43, no. 9, pp. 1128–1136, 2008. View at Publisher · View at Google Scholar · View at PubMed
74. A. Uygun, A. Kadayifci, Z. Yesilova, et al., “Serum leptin levels in patients with nonalcoholic steatohepatitis,” The American Journal of Gastroenterology, vol. 95, no. 12, pp. 3584–3589, 2000. View at Publisher · View at Google Scholar
75. E. Bugianesi, U. Pagotto, R. Manini, et al., “Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity,” The Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 6, pp. 3498–3504, 2005. View at Publisher · View at Google Scholar · View at PubMed
76. J. M. Hui, A. Hodge, G. C. Farrell, J. G. Kench, A. Kriketos, and J. George, “Beyond insulin resistance in NASH: TNF-$\alpha$ or adiponectin?,” Hepatology, vol. 40, no. 1, pp. 46–54, 2004. View at Publisher · View at Google Scholar · View at PubMed
77. M. Shimada, H. Kawahara, K. Ozaki, et al., “Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis,” The American Journal of Gastroenterology, vol. 102, no. 9, pp. 1931–1938, 2007. View at Publisher · View at Google Scholar · View at PubMed
78. Z. M. Younossi, M. Jarrar, C. Nugent, et al., “A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH),” Obesity Surgery, vol. 18, no. 11, pp. 1430–1437, 2008. View at Publisher · View at Google Scholar · View at PubMed
79. A. Y.-H. Wang, I. J. Hickman, A. A. Richards, J. P. Whitehead, J. B. Prins, and G. A. MacDonald, “High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection,” The American Journal of Gastroenterology, vol. 100, no. 12, pp. 2717–2723, 2005. View at Publisher · View at Google Scholar · View at PubMed
80. M. Nannipieri, F. Cecchetti, M. Anselmino, et al., “Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis,” Obesity Surgery, vol. 19, no. 4, pp. 467–474, 2009. View at Publisher · View at Google Scholar · View at PubMed
81. H. Ma, V. Gomez, L. Lu, X. Yang, X. Wu, and S.-Y. Xiao, “Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease,” Journal of Gastroenterology and Hepatology, vol. 24, no. 2, pp. 233–237, 2009. View at Publisher · View at Google Scholar · View at PubMed
82. S. Kaser, A. Maschen, A. Cayon, et al., “Adiponectin and its receptors in non-alcoholic steatohepatitis,” Gut, vol. 54, no. 1, pp. 117–121, 2005. View at Publisher · View at Google Scholar · View at PubMed
83. G. Musso, R. Gambino, F. De Michieli, M. Durazzo, G. Pagano, and M. Cassader, “Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH,” Hepatology, vol. 47, no. 4, pp. 1167–1177, 2008. View at Publisher · View at Google Scholar · View at PubMed
84. S. Abiru, K. Migita, Y. Maeda, et al., “Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis,” Liver International, vol. 26, no. 1, pp. 39–45, 2006. View at Publisher · View at Google Scholar · View at PubMed
85. V. W. Wong, A. Y. Hui, S. W. Tsang, et al., “Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease,” Clinical Gastroenterology and Hepatology, vol. 4, no. 9, pp. 1154–1161, 2006. View at Publisher · View at Google Scholar · View at PubMed
86. M. H. Jarrar, A. Baranova, R. Collantes, et al., “Adipokines and cytokines in non-alcoholic fatty liver disease,” Alimentary Pharmacology and Therapeutics, vol. 27, no. 5, pp. 412–421, 2008. View at Publisher · View at Google Scholar · View at PubMed
87. C. Pagano, G. Soardo, C. Pilon, et al., “Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance,” The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 3, pp. 1081–1086, 2006.
88. A. Wieckowska, B. G. Papouchado, Z. Li, R. Lopez, N. N. Zein, and A. E. Feldstein, “Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis,” The American Journal of Gastroenterology, vol. 103, no. 6, pp. 1372–1379, 2008. View at Publisher · View at Google Scholar · View at PubMed
89. D. García-Galiano, M. A. Sánchez-Garrido, I. Espejo, et al., “IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients,” Obesity Surgery, vol. 17, no. 4, pp. 493–503, 2007. View at Publisher · View at Google Scholar · View at PubMed
90. J. W. Haukeland, J. K. Damås, Z. Konopski, et al., “Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2,” Journal of Hepatology, vol. 44, no. 6, pp. 1167–1174, 2006. View at Publisher · View at Google Scholar · View at PubMed
91. J. A. Seo, N. H. Kim, S. Y. Park, et al., “Serum retinol-binding protein 4 levels are elevated in non-alcoholic fatty liver disease,” Clinical Endocrinology, vol. 68, no. 4, pp. 555–560, 2008. View at Publisher · View at Google Scholar · View at PubMed
92. R. Aller, D. A. de Luis, O. Izaola, et al., “Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease,” to appear in Digestive Diseases and Sciences. View at Publisher · View at Google Scholar · View at PubMed
93. L. A. Adams, C. O. Zein, P. Angulo, and K. D. Lindor, “A pilot trial of pentoxifylline in nonalcoholic steatohepatitis,” The American Journal of Gastroenterology, vol. 99, no. 12, pp. 2365–2368, 2004. View at Publisher · View at Google Scholar · View at PubMed
94. S. K. Satapathy, P. Sakhuja, V. Malhotra, B. C. Sharma, and S. K. Sarin, “Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis,” Journal of Gastroenterology and Hepatology, vol. 22, no. 5, pp. 634–638, 2007. View at Publisher · View at Google Scholar · View at PubMed
95. S. S. Koca, I. H. Bahcecioglu, O. K. Poyrazoglu, I. H. Ozercan, K. Sahin, and B. Ustundag, “The treatment with antibody of TNF-$\alpha$ reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet,” Inflammation, vol. 31, no. 2, pp. 91–98, 2008. View at Publisher · View at Google Scholar · View at PubMed
96. S. Naveau, S. Chollet-Martin, S. Dharancy, et al., “A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis,” Hepatology, vol. 39, no. 5, pp. 1390–1397, 2004. View at Publisher · View at Google Scholar · View at PubMed
97. R. Belfort, S. A. Harrison, K. Brown, et al., “A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis,” The New England Journal of Medicine, vol. 355, no. 22, pp. 2297–2307, 2006. View at Publisher · View at Google Scholar · View at PubMed
98. J. S. Smolen, A. Beaulieu, A. Rubbert-Roth, et al., “Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial,” The Lancet, vol. 371, no. 9617, pp. 987–997, 2008. View at Publisher · View at Google Scholar · View at PubMed